OncLive | FDA Approves Frontline Obinutuzumab for CLL OncLive In the three-arm study, patients were randomized in a 1:2:2 ratio to receive six cycles every 28 days of chlorambucil (n = 118), chlorambucil plus obinutuzumab (n = 238), or chlorambucil plus rituximab (n = 233). An additional 192 patients were ... |
